Find similar products:
The text only version may be available in large print, Braille or audio CD. For further information call emc accessibility on 0800 198 5000. The product code(s) for this leaflet is: PL 08553/0761.
Teriflunomide 14 mg Film-Coated Tablets
Teriflunomide 14 mg film-coated tablets
teriflunomide
1. What Teriflunomide is and what it is used for
2. What you need to know before you take Teriflunomide
3. How to take Teriflunomide
4. Possible side effects
5. How to store Teriflunomide
6. Contents of the pack and other information
Teriflunomide film-coated tablet contains the active substance teriflunomide which is an immunomodulatory agent and adjusts the immune system to limit its attack on the nervous system.
Teriflunomide is used in adults and in children and adolescents (10 years of age and older) to treat relapsing remitting multiple sclerosis (MS).
MS is a long-term illness that affects the central nervous system (CNS). The CNS is made up of the brain and spinal cord. In multiple sclerosis, inflammation destroys the protective sheath (called myelin) around the nerves in the CNS. This loss of myelin is called demyelination. This stops nerves from working properly.
People with relapsing form of multiple sclerosis will have repeated attacks (relapses) of physical symptoms caused by their nerves not working properly. These symptoms vary from patient to patient but usually involve:
Symptoms may disappear completely after the relapse is over, but over time, some problems may remain between relapses. This can cause physical disabilities that may interfere with your daily activities.
Teriflunomide helps to protect against attacks on the central nervous system by the immune system by limiting the increase of some white blood cells (lymphocytes). This limits the inflammation that leads to nerve damage in MS.
If you are not sure, talk to your doctor or pharmacist before taking this medicine.
Talk to your doctor or pharmacist before taking teriflunomide if:
Tell your doctor if you have unexplained cough and dyspnoea (shortness of breath). Your doctor may perform additional tests.
Teriflunomide is not intended for use in children under 10 years of age, as it has not been studied in MS patients in this age group.
The warnings and precautions listed above also apply to children. The following information is important for children and their caregivers:
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. This includes medicines obtained without a prescription.
In particular, tell your doctor or pharmacist if you are taking any of the following:
Do not take teriflunomide if you are or think you may be pregnant. If you are pregnant or become pregnant while taking teriflunomide, the risk of having a baby with birth defects is increased. Women of childbearing potential must not take this medicine without using reliable contraceptive measures.
If your daughter reaches menses while taking teriflunomide, you should inform the doctor, who will provide specialist counselling regarding contraception and the potential risks in case of pregnancy.
Tell your doctor if you plan to become pregnant after stopping treatment with teriflunomide, as you need to ensure that most of this medicine has left your body before trying to become pregnant. The elimination of the active substance may take up to 2 years to occur naturally. The time can be reduced to a few weeks by taking certain medicines which speed up removal of teriflunomide from your body.
In either case it should be confirmed by a blood test that the active substance has been sufficiently removed from your body and you need confirmation from your treating physician that the blood level of teriflunomide is low enough to allow you to become pregnant.
For further information on the laboratory testing please contact your doctor.
If you suspect that you are pregnant while taking teriflunomide or in the two years after you have stopped treatment, you must discontinue teriflunomide and contact your doctor immediately for a pregnancy test. If the test confirms that you are pregnant, your doctor may suggest treatment with certain medicines to remove teriflunomide rapidly and sufficiently from your body, as this may decrease the risk to your baby.
Contraception
You must use an effective method of contraception during and after treatment with teriflunomide. Teriflunomide remains in your blood for a long time after you stop taking it. Continue to use effective contraception after you stop treatment.
Do not take teriflunomide when you are breast-feeding, as teriflunomide passes into the breast milk.
Teriflunomide might make you feel dizzy which may impair your ability to concentrate and react. If you are affected, do not drive or use machines.
Teriflunomide contains lactose (a type of sugar). If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicine.
This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially ‘sodium-free’.
Always take this medicine exactly as your doctor has told you. Check with your doctor if you are not sure.
Treatment with Teriflunomide will be overseen by a doctor who is experienced in the treatment of multiple sclerosis.
The recommended dose is one 14 mg tablet daily.
The dose depends on body weight:
Children and adolescents who reach a stable body weight above 40 kg will be instructed by their doctor to switch to one 14 mg tablet daily.
Route/method of administration
Teriflunomide is for oral use.
Teriflunomide is taken every day as a single dose at any time of the day.
You should swallow the tablet whole with some water.
Teriflunomide may be taken with or without food.
If you have taken too much Teriflunomide, call your doctor straight away. You may experience side effects similar to those described in section 4 below.
Do not take a double dose to make up for a forgotten tablet. Take your next dose at the scheduled time.
Do not stop taking Teriflunomide or change your dose without talking to your doctor first.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
The following side effects may happen with this medicine.
Some side effects could be or could become serious, if you experience any of these, tell your doctor immediately.
Common (may affect up to 1 in 10 people)
Uncommon (may affect up to 1 in 100 people)
Not known (frequency cannot be estimated from the available data):
Other side effects can occur with the following frequencies:
Very common (may affect more than 1 in 10 people)
Common (may affect up to 1 in 10 people)
Uncommon (may affect up to 1 in 100 people)
Rare (may affect up to 1 in 1,000 people)
Not known (frequency cannot be estimated from the available data)
The side effects listed above also apply to children and adolescents. The following additional information is important for children, adolescents, and their caregivers:
Common (may affect up to 1 in 10 people)
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme website www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the carton after “EXP”. The expiry date refers to the last day of that month.
This medicine does not require any special storage conditions.
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.
The active substance is teriflunomide.
Each tablet contains 14 mg of teriflunomide.
The other ingredients are lactose monohydrate, cellulose microcrystalline, maize starch, sodium starch glycolate (Type A), hydroxypropylcellulose, magnesium stearate, hypromellose, calcium carbonate, triacetin, indigo carmine aluminium lake (E132).
Teriflunomide 14 mg film-coated tablets are round, blue, 7 mm in diameter and marked “C14” on one side.
Pack sizes: 28, 56, 84 or 98 film-coated tablets
Not all pack sizes may be marketed.
Marketing Authorisation Holder:
Manufacturer:
This leaflet was last revised in September 2024.